한글목차

세계의 HERG 스크리닝 시장 규모는 예측 기간 중 CAGR로 12.50%의 성장이 예측됩니다.

지역의 인사이트

북미 시장이 2022년에 시장을 선도했습니다(45.80%).

유럽 시장은 2022년에 건전한 시장 점유율을 차지했습니다. 유럽의 서부·동부 지역이 시장의 대부분을 차지하고 있으며, 주요 기여자로 간주되고 있습니다.

아시아태평양 시장은 2023-2032년에 중대한 발전을 보일 전망입니다.

세계의 HERG 스크리닝 시장에 대해 조사분석했으며, 시장 역학, 지역과 부문 분석, 기업 개요 등을 제공하고 있습니다.

목차

제1장 주요 요약

제2장 시장의 서론

제3장 조사 방법

제4장 시장 역학

• 개요
• 촉진요인
  • 신약 승인의 증가
  • 심장병의 유병률 증가
• 억제요인
  • HERG 스크리닝 제품의 고비용
• 기회
  • 미개척 시장
• COVID-19의 영향
  • 개요
  • 기업에 대한 영향
  • 임상시험에 대한 영향

제5장 시장 요인 분석

• 공급망 분석
  • 연구개발, 설계
  • 제조
  • 유통
  • 마케팅, 판매
  • 판매 후 모니터링
• PORTER'S FIVE FORCES 모델
• 세계의 HERG 스크리닝 시장의 기술 동향
  • HERG 서비스 아웃소싱의 증가 동향
  • 패치 클램프 어세이의 등장
  • 시장 기업에 의한 전략적 구상
• 고객 요구 분석
  • 개요
  • HERG 스크리닝의 임상시험
  • 원인과 결과 분석

제6장 세계의 HERG 스크리닝 시장 : 유형별

• 개요
• 유전자 KCNH2
• 변이 KCNH2

제7장 세계의 HERG 스크리닝 시장 : 이온채널별

• 개요
• 전위 의존성 이온채널
• 리간드 의존성 이온채널
• 기타

제8장 세계의 HERG 스크리닝 시장 : 용도별

• 개요
• 항부정맥약
• 항정신병약
• 항생제
• 기타

제9장 세계의 HERG 스크리닝 시장 : 지역별

• 개요
• 미국
  • 북미
  • 라틴아메리카
• 유럽
  • 서유럽
  • 동유럽
• 아시아태평양
  • 중국
  • 일본
  • 인도
  • 호주
  • 한국
  • 기타 아시아태평양
• 중동 및 아프리카
  • 중동
  • 아프리카

제10장 경쟁 구도

• 개요
• 시장 순위 분석
• 경쟁 벤치마킹
• 주요 발전과 성장 전략
  • 파트너십
  • 인수
  • 제휴
• 주요 기업의 재무 매트릭스와 시장 비율
  • 판매, 영업이익률
  • 연구개발비

제11장 기업 개요

• THERMO FISHER SCIENTIFIC INC.
• CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
• MERCK KGAA
• EUROFINS DISCOVERX CORPORATION
• ABCAM PLC.
• CYPROTEX LIMITED
• B'SYS GMBH
• CREATIVE BIOARRAY
• METRION BIOSCIENCES LTD
• AURORA BIOMED INC.

제12장 부록

영문목차

Market Overview

The HERG Screening Market is anticipated to register a significant CAGR of 12.50% during the forecast period. The rising endorsement of imaginative medications and the ascent in coronary illness commonness are the major market drivers contributing the market development.

As coronary illness is common and the quantity of heart condition patients both ascents, the market is supposed to develop. The market is developing because of expanded Research and development exercises on the side of new item deliveries. Furthermore, it is extended that an ascent in the quantity of creative medication substance endorsements will uphold the market's development. The market is developing as a direct result of both the making of solutions for diseases and problems and the ascent of popularity for drug plans.

Because of the development in examples of cardiotoxicity, there has been a critical interest in screening materials utilized in drug creation. Customary testing techniques may not generally be preferable over HERG tests, yet they might be more secure and more effective when utilized on prescriptions. Cardiovascular medications are progressively having unfavorable aftereffects in patients with prior heart conditions. Cardiotoxicity is more normal in patients who have had malignant growth treatment or cardiovascular medical procedures. Subsequently, there is a rising interest in hardware and administrations that empower productive cardiotoxicity testing. The heart makes some harder memories completing typical capabilities and disseminating blood all through the body when there is cardiotoxicity. Cardiotoxicity thus expands the gamble of cardiomyopathy, which decreases the heart's ability to siphon blood.

Market Segmentation

The HERG Screening market segmentation, based on Type, includes Gene KCNH2 and Mutant KCNH2.

The HERG Screening market segmentation, based on Ion Channel, includes Voltage Gated and Ligand Gated. Based on Application the market is classified into Antiarrhythmic, Antipsychotic, Antibiotics, and Others.

Regional Insights

The North American HERG Screening Market led the market in 2022 (45.80%). At regular intervals, a resident of the US will encounter a myocardial dead tissue, as per the American School of Cardiology. In 2017, 356,460 Americans went through an out-of-clinic heart failure, and in 52% of those cases, crisis clinical benefits were called.

Europe HERG Screening market represented the sound market share in 2022. Europe's western and eastern regions make up most of the market for HERG screening and are both viewed as major contributors.

The Asia Pacific HERG Screening market is supposed to enroll in critical development from 2023 to 2032. A critical part of individuals in space has persistent heart conditions, and the occurrence of fiery problems is rising rapidly too.

Major Players

Major players in the HERG Screening market are Eurofins Scientific, Charles River Laboratories, Merck KGaA, Cyprotex Limited, Creative Bioarray, BSYS GmbH, Aurora Biomed, and Metrion Biosciences.

TABLE OF CONTENTS

1 EXECUTIVE SUMMARY

• 1.1 MARKET SYNOPSIS 14
• 1.2 MARKET ATTRACTIVENESS ANALYSIS 15

2 MARKET INTRODUCTION

• 2.1 DEFINITION 16
• 2.2 SCOPE OF THE STUDY 16
• 2.3 RESEARCH OBJECTIVE 16
• 2.4 MARKET STRUCTURE 16
• 2.5 ASSUMPTIONS & LIMITATIONS 17

3 RESEARCH METHODOLOGY

• 3.1 DATA MINING 18
• 3.2 SECONDARY RESEARCH 19
• 3.3 PRIMARY RESEARCH 20
• 3.4 BREAKDOWN OF PRIMARY RESPONDENTS 21
• 3.5 FORECASTING TECHNIQUES 21
• 3.6 RESEARCH METHODOLOGY FOR MARKET SIZE ESTIMATION 22
  • 3.6.1 BOTTOM-UP APPROACH 23
  • 3.6.2 TOP-DOWN APPROACH 23
• 3.7 DATA TRIANGULATION 24
• 3.8 VALIDATION 24

4 MARKET DYNAMICS

• 4.1 OVERVIEW 25
• 4.2 DRIVERS 26
  • 4.2.1 INCREASING NOVEL DRUG APPROVALS 26
  • 4.2.2 INCREASING PREVALENCE OF HEART DISEASES 26
• 4.3 RESTRAINT 27
  • 4.3.1 HIGH COST OF HERG SCREENING PRODUCTS 27
• 4.4 OPPORTUNITY 28
  • 4.4.1 UNTAPPED MARKETS 28
• 4.5 IMPACT OF CORONAVIRUS (COVID)-19 28
  • 4.5.1 OVERVIEW 28
  • 4.5.2 IMPACT ON PLAYERS 28
  • 4.5.3 IMPACT ON CLINICAL TRIALS 28

5 MARKET FACTOR ANALYSIS

• 5.1 SUPPLY CHAIN ANALYSIS 29
  • 5.1.1 R&D AND DESIGNING 29
  • 5.1.2 MANUFACTURING 30
  • 5.1.3 DISTRIBUTION 30
  • 5.1.4 MARKETING & SALES 30
  • 5.1.5 POST-SALES MONITORING 30
• 5.2 PORTER'S FIVE FORCES MODEL 30
  • 5.2.1 BARGAINING POWER OF SUPPLIERS 31
  • 5.2.2 BARGAINING POWER OF BUYERS 31
  • 5.2.3 THREAT OF NEW ENTRANTS 32
  • 5.2.4 THREAT OF SUBSTITUTES 32
  • 5.2.5 RIVALRY 32
• 5.3 TECHNOLOGICAL TRENDS IN GLOBAL HERG SCREENING MARKET 32
  • 5.3.1 INCREASING TREND OF OUTSOURCING HERG SERVICES 32
  • 5.3.2 ADVENT OF PATCH CLAMP ASSAY 33
  • 5.3.3 STRATEGIC INITIATIVES BY PLAYERS IN THE MARKET 33
• 5.4 CUSTOMER NEED ANALYSIS 33
  • 5.4.1 OVERVIEW 33
  • 5.4.2 CLINICAL TRIAL FOR HERG SCREENING 33
  • 5.4.3 CAUSE AND EFFECT ANALYSIS 34

6 GLOBAL HERG SCREENING MARKET, BY TYPE

• 6.1 OVERVIEW 35
• 6.2 GENE KCNH2 36
• 6.3 MUTANT KCNH2 36

7 GLOBAL HERG SCREENING MARKET, BY ION CHANNEL

• 7.1 OVERVIEW 37
• 7.2 VOLTAGE-GATED ION CHANNEL 39
• 7.3 LIGAND-GATED ION CHANNEL 39
• 7.4 OTHERS 40

8 GLOBAL HERG SCREENING MARKET, BY APPLICATION

• 8.1 OVERVIEW 41
• 8.2 ANTIARRHYTHMIC 43
• 8.3 ANTIPSYCHOTIC 43
• 8.4 ANTIBIOTIC 43
• 8.5 OTHERS 44

9 GLOBAL HERG SCREENING MARKET, BY REGION

• 9.1 OVERVIEW 45
• 9.2 AMERICAS 47
  • 9.2.1 NORTH AMERICA 49
    • 9.2.1.1 US 51
    • 9.2.1.2 CANADA 52
  • 9.2.2 LATIN AMERICA 53
• 9.3 EUROPE 54
  • 9.3.1 WESTERN EUROPE 56
    • 9.3.1.1 GERMANY 58
    • 9.3.1.2 FRANCE 59
    • 9.3.1.3 UK 60
    • 9.3.1.4 ITALY 61
    • 9.3.1.5 SPAIN 62
    • 9.3.1.6 REST OF WESTERN EUROPE 63
  • 9.3.2 EASTERN EUROPE 64
• 9.4 ASIA-PACIFIC 65
  • 9.4.1 CHINA 67
  • 9.4.2 JAPAN 68
  • 9.4.3 INDIA 69
  • 9.4.4 AUSTRALIA 70
  • 9.4.5 SOUTH KOREA 71
  • 9.4.6 REST OF ASIA-PACIFIC 72
• 9.5 MIDDLE EAST & AFRICA 73
  • 9.5.1 MIDDLE EAST 75
  • 9.5.2 AFRICA 76

10 COMPETITIVE LANDSCAPE

• 10.1 OVERVIEW 77
• 10.2 MARKET RANKING ANALYSIS 77
• 10.3 COMPETITIVE BENCHMARKING 78
• 10.4 KEY DEVELOPMENTS AND GROWTH STRATEGIES 79
  • 10.4.1 PARTNERSHIP 79
  • 10.4.2 ACQUISITIONS 80
  • 10.4.3 COLLABORATION 80
• 10.5 MAJOR PLAYERS FINANCIAL MATRIX & MARKET RATIO 81
  • 10.5.1 SALES & OPERATING PROFIT MARGIN 81
  • 10.5.2 R&D EXPENDITURE 81

11 COMPANY PROFILES

• 11.1 THERMO FISHER SCIENTIFIC INC. 82
  • 11.1.1 COMPANY OVERVIEW 82
  • 11.1.2 FINANCIAL OVERVIEW 82
  • 11.1.3 PRODUCTS/SERVICES OFFERED 83
  • 11.1.4 KEY DEVELOPMENTS 83
  • 11.1.5 SWOT ANALYSIS 83
  • 11.1.6 KEY STRATEGIES 83
• 11.2 CHARLES RIVER LABORATORIES INTERNATIONAL, INC. 84
  • 11.2.1 COMPANY OVERVIEW 84
  • 11.2.2 FINANCIAL OVERVIEW 84
  • 11.2.3 PRODUCTS/SERVICES OFFERED 85
  • 11.2.4 KEY DEVELOPMENTS 85
  • 11.2.5 SWOT ANALYSIS 86
  • 11.2.6 KEY STRATEGIES 86
• 11.3 MERCK KGAA 87
  • 11.3.1 COMPANY OVERVIEW 87
  • 11.3.2 FINANCIAL OVERVIEW 87
  • 11.3.3 PRODUCTS/SERVICES OFFERED 88
  • 11.3.4 KEY DEVELOPMENTS 88
  • 11.3.5 SWOT ANALYSIS 88
  • 11.3.6 KEY STRATEGIES 88
• 11.4 EUROFINS DISCOVERX CORPORATION 89
  • 11.4.1 COMPANY OVERVIEW 89
  • 11.4.2 FINANCIAL OVERVIEW 89
  • 11.4.3 PRODUCTS/SERVICES OFFERED 90
  • 11.4.4 KEY DEVELOPMENTS 90
  • 11.4.5 SWOT ANALYSIS 90
  • 11.4.6 KEY STRATEGIES 91
• 11.5 ABCAM PLC. 92
  • 11.5.1 COMPANY OVERVIEW 92
  • 11.5.2 FINANCIAL OVERVIEW 92
  • 11.5.3 PRODUCTS/SERVICES OFFERED 93
  • 11.5.4 KEY DEVELOPMENTS 93
  • 11.5.5 SWOT ANALYSIS 94
  • 11.5.6 KEY STRATEGIES 94
• 11.6 CYPROTEX LIMITED 95
  • 11.6.1 COMPANY OVERVIEW 95
  • 11.6.2 FINANCIAL OVERVIEW 95
  • 11.6.3 PRODUCTS/SERVICES OFFERED 95
  • 11.6.4 KEY DEVELOPMENTS 95
  • 11.6.5 SWOT ANALYSIS 96
  • 11.6.6 KEY STRATEGIES 96
• 11.7 B'SYS GMBH 97
  • 11.7.1 COMPANY OVERVIEW 97
  • 11.7.2 FINANCIAL OVERVIEW 97
  • 11.7.3 PRODUCTS/SERVICES OFFERED 97
  • 11.7.4 KEY DEVELOPMENTS 97
  • 11.7.5 SWOT ANALYSIS 98
  • 11.7.6 KEY STRATEGIES 98
• 11.8 CREATIVE BIOARRAY 99
  • 11.8.1 COMPANY OVERVIEW 99
  • 11.8.2 FINANCIAL OVERVIEW 99
  • 11.8.3 PRODUCTS/SERVICES OFFERED 99
  • 11.8.4 KEY DEVELOPMENTS 99
  • 11.8.5 SWOT ANALYSIS 100
  • 11.8.6 KEY STRATEGIES 100
• 11.9 METRION BIOSCIENCES LTD 101
  • 11.9.1 COMPANY OVERVIEW 101
  • 11.9.2 FINANCIAL OVERVIEW 101
  • 11.9.3 PRODUCTS/SERVICES OFFERED 101
  • 11.9.4 KEY DEVELOPMENTS 101
  • 11.9.5 SWOT ANALYSIS 102
  • 11.9.6 KEY STRATEGIES 102
• 11.10 AURORA BIOMED INC. 103
  • 11.10.1 COMPANY OVERVIEW 103
  • 11.10.2 FINANCIAL OVERVIEW 103
  • 11.10.3 PRODUCTS/SERVICES OFFERED 103
  • 11.10.4 KEY DEVELOPMENTS 103
  • 11.10.5 SWOT ANALYSIS 104
  • 11.10.6 KEY STRATEGIES 104

12 APPENDIX

• 12.1 REFERENCES 105
• 12.2 RELATED REPORTS 105